Anti-Human PD-1 & CTLA-4 Reference Antibody (Volrustomig, RUO) (HS870396)

Name: Anti-Human PD-1 & CTLA-4 Reference Antibody (Volrustomig, RUO)
Brand: abinScience
SKU: HS870396
Price: 220 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	HS870396
Описание	Volrustomig (HS870396) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Реактивность видов	Human
Применения	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Хозяинский вид	Human
Клоональность	Monoclonal
Изотип	IgG1-kappa/kappa-lambda
Проверенные приложения	WB
Цель	CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1, CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	Q15116 & P16410
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	2407760-40-9
Фон	Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody. • Cancer immunotherapy using checkpoint blockade., PMID:29567705 • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • Immune-related adverse events of checkpoint inhibitors., PMID:32382051 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113 • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885 • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160 • Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858 • Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360 • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Примечание	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)

Изображения

Bioactivity

Detects recombinant human PD1 (Cat No.: HS870021) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CD152/CTLA4 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD152/CTLA4 (Catalog No: HB651011)
Lane 2: negative control